Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Examine the Biogenerics, the World Market: Biosimilars and Biologics at a Crossroads
Examine the Biogenerics, the World Market: Biosimilars and Biologics at a Crossroads

LONDON, UNITED KINGDOM -- (MARKET WIRE) -- 04/16/08 -- Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue.

Biogenerics, The World Market: Biosimilars and Biologics at a Crossroads

http://www.reportlinker.com/p087179/Biogenerics-The-World-Market-Biosimi...

The biopharmaceutical market is at a crossroads. Some of the biggest-selling biologics developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, have lost patent protection or are set to lose patent protection in the US in 2007 and beyond. This opens up the market currently worth $40 billion and growing at over 20% per year if the regulatory hurdles can be overcome.

In this report, Biogenerics, The World Market: Biosimilars and Biologics at a Crossroads Kalorama has identified key biologic products that are off patent and are either facing development of a generic competitor or are likely in Kalorama's estimate to face biogeneric competition in the future.

Since Kalorama Information last visited the market for synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies four years ago, there has been much more worldwide involvement in the development of the biogeneric arena.

Kalorama Information's survey includes as part of its market analysis a breakdown of generic replacements for:

- Drugs with Active patents

- Drugs with Expired patents

with this geographic breakdown:

- World

- US

- non-US

As part of overall market coverage of biogenerics, this report includes:

- Complete Overview

- Market Size Projections for Biogenerics Products

- Patent dates for Major Biopharmaceuticals

- Issues and Trends in the Industry

- Scientific Differences Between Biopharmaceuticals and Biogenerics

- Key Regulations Affecting this Market

- Company Profiles

The following critical trends occuring in biogenerics are discussed:

- Worldwide Regulatory and Legislative Issues

- Asia and Biogenerics

- Scientific Issues

- Patent Issues

- Pricing Issues

- Barriers to Entry

- Innovator Strategies and Challenges

- Bulk Suppliers and Contract Manufacturing

- Bioequivalence Issues

- International Issues

- Low Cost Branded HGH

- Biogenerics and Health-Care Spending

- Intellectual Property

As part of Kalorama Information's trusted information gathering process, this report is the result of both primary and secondary research. In addition to exhaustive research, Key executives at biogeneric companies were consulted to uncover key trends and develop models.

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

- Introduction

- Scope and Methodology

- Size and Growth of the Market

- Trends Affecting the Market

- Market Outlook

CHAPTER TWO: INTRODUCTION AND OVERVIEW

- Biogenerics Overview

- Biopharmaceutical Industry and Approval Process

-- Genetic Engineering Patent Approval

- Regulations for Biopharmaceuticals

- History of the Prescription Generic Pharmaceuticals Industry

- History of the Generic Approval Process

- Regulation of Prescription Generic Pharmaceuticals

- Biopharmaceuticals

- Areas of Treatment for Biopharmaceuticals

CHAPTER THREE: BIOGENERIC PHARMACEUTICALS FOR EXPIRED BIOLOGIC PATENTS

- Market Size and Growth

- Non-U.S. Market

CHAPTER FOUR: BIOGENERIC PHARMACEUTICALS FOR FUTURE EXPIRED BIOLOGIC PATENTS

- Market Size and Growth

-- World Market

-- Non-U.S. Market

CHAPTER FIVE: ISSUES AND TRENDS

- Overview

- Worldwide Regulatory and Legislative Issues

-- Europe

-- United States

-- Rest of World

- Asia and Biogenerics

- Scientific Issues

- Patent Issues

- Pricing Issues

- Barriers to Entry

- Innovator Strategies and Challenges

- Bulk Suppliers and Contract Manufacturing

- Bioequivalence Issues

- International Issues

- Low Cost Branded HGH

- Biogenerics and Health-Care Spending

- Intellectual Property

CHAPTER SIX: MARKET SUMMARY

- Total Market Size and Forecast

- Competitor Analysis

CHAPTER SEVEN: CORPORATE PROFILES

- Analiza, Inc

- Apotex, Inc.

- Barr Laboratories, Inc.

- Biogenerix Ag

- Biocon Ltd.

- BioPartners GmbH

- Cangene Corporation

- Dr. Reddy's Laboratories Limited

- Dragon Pharmaceuticals, Inc.

- GeneMedix PLC

- Hospira, Inc.

- Microbix Biosystems, Inc.

- Momenta Pharmaceuticals Inc

- Phage Biotechnology Corp

- Sandoz

- Sicor, Inc.

- STADA Arzneimittel AG

- TEVA Pharmaceutical Industries, Ltd.

- Watson Pharmaceuticals, Inc.

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

- Table 1-1: Total World Biogenerics Market Potential 2006-2012

- Figure 1-1: The World Market Potential for BioGeneric Drugs by Revenues 2006-2012

INTRODUCTION AND OVERVIEW

- Table 2-1: Scientific Differences of Pharmaceuticals and Biopharmaceuticals

CHAPTER THREE: BIOGENERIC PHARMACEUTICALS FOR EXPIRED BIOLOGIC PATENTS

- Table 3-2: Marketed Biopharmaceuticals with Expired Patents

- Table 3-3: Total World Biogenerics Market Potential 2006-2012, Products with Expired Patents

- Table 3-4: Total U.S. Biogenerics Market Potential 2006-2012, Products with Expired Patents Table 3-5: Total Non-U.S. Biogenerics Market Potential 2006-2012, Products with Expired Patents

CHAPTER FOUR: BIOGENERIC PHARMACEUTICALS FOR FUTURE EXPIRED BIOLOGIC PATENTS

- Table 4-1: Marketed Biopharmaceuticals with Active Patents

- Table 4-2: Total World Biogenerics Market Potential 2006-2012, Products with Active Patents

- Table 4-3: Total U.S. Biogenerics Market Potential 2006-2012, Products with Active Patents

- Table 4-4: Total Non-U.S. Biogenerics Market Potential 2006-2012, Products with Active Patents

CHAPTER FIVE: ISSUES AND TRENDS

- Table 5-1: Estimates of Treatment Cost Per Patient of Selected Biopharmaceuticals

CHAPTER SIX: MARKET ANALYSIS

- Table 6-1: Total World Biogenerics Market Potential 2006-2012

- Table 6-2: The World Market Potential for BioGeneric Drugs by Patent Segment 2006-2012

- Figure 6-1 Total World Biogenerics Market Potential 2006-2012 (Active, Expired)

- Figure 6-2 The World Market Potential for BioGeneric Drugs by Patent Segment (Active, Expired) 2006-2012

To order this report:

Biogenerics, The World Market: Biosimilars and Biologics at a Crossroads

http://www.reportlinker.com/p087179/Biogenerics-The-World-Market-Biosimi...

More market research reports here!

Contacts:
Reportlinker.com
Nicolas
(718) 887-3024
Email: nbo@reportlinker.com

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Cloud Developer Stories
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, an...
SYS-CON Events announced today that Conference Guru has been named “Media Sponsor” of the 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. A valuable conference experience generates new contacts, sales leads, potentia...
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (Clo...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enter...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE